About addmedica

Founded in 2005, Addmedica is a European-based privately owned Specialty Pharma Company focused on developing and marketing medical products for Rare Diseases and Niche Markets.
By developing, registering and/or marketing dedicated medical products (medicinal products, medical devices or diagnosis) in rare and debilitating diseases, the mission of Addmedica is to provide Physicians, Patients and Managed Care Organizations with high medical value solutions.
The company’s growth is driven by an original business model, including partnerships, specially adapted to the development, marketing and distribution of innovative and original products dedicated to rare diseases, serious conditions and unmet medical needs.

Unlike classical pharma start-ups and due to the entrepreneurial spirit of the founders, the company began its business by commercializing products mainly under licences and gradually reinvested its revenues in R&D programs at increasingly early stages. Since its incorporation in 2005, the growth rate of the company was only based on its capability to self-financing from its own development. With this positive financial profile, enabling Addmedica to invest in its future, the company has currently a complete portfolio of developing products from early stage development to market phase.
On the  strength of this credible and robust platform for adding new products, in early 2019, Addmedica opened its capital structure to MERIEUX Development in order to speed up and develop the company with an extended portfolio in new territories.

At Addmedica, only key and stategic functions are managed in house, notably Regulatory Affairs and Scientific, Medical and Marketing Expertise with experience of EU Centralized MA and US Approval, Named Patient and Early Access Program management and commercialization of an Orphan Drug throughout Europe and in the US. Addmedica is used to working with a network of high quality suppliers, Consultants and Partners for specific needs (i.e. labs research, manufacturing, clinical trials, medical affairs expertise, market access process, business development and licences…). If appropriate, Addmedica is also able to set up its own distribution structure in a territory including its own sales force in its areas of expertise (i.e. in France).
Addmedica’s main premises are located in Paris.

Addmedica has a strong interest in hematology and wound-healing.
Addmedica is currently one of the main worldwide actors in sickle cell disease (SCD), an orphan hematologic disease, since the company commercialises a reference treatment. The company regularly publishes results of breakthrough in this disease. Addmedica is a member of the Sickle cell Coalition and a partner of several groups and/or associations involved in SCD worldwide.
Besides this main product, Addmedica markets cyanoacrylate glue with a position of market leader in France with LiquiBand^®.

Addmedica also has a good track record in transplantation.
Currently a patented project in this field is under development.
Addmedica has recently signed an agreement with a new patented development in life-threatening anaphylaxy crisis.
This high potential product in emergency market will allow the company to expand its operational capabilities in the early next decade.
Other collaborative projects are at different stages of development and cover several rare diseases or life-threatening conditions, i.e. Wilson disease, Mitochrondrial diseases, Central retinal vein occlusion.

Addmedica has a sustained Business Development Strategy.
Thanks to its structure with multiple expertise and competences, the company can discuss with third-party entities (Institutional Researches entities, Universities, Patients Associations or other Pharmaceutical Companies) that need clinical or regulatory development advice.
The company is particularly open-minded to projects in the scope of
– Genetic diseases, drug or substitute therapies, cell or gene therapies
– Wound healing, high level surgery, tissue growth and cell regeneration
– Organ transplant and tissue replacement
– Redevelopment of well-known molecules in innovative and/or rare indications
Addmedica has developed a credible and robust platform for adding new products and developing the company on a regional or worldwide basis. Addmedica is ready for successful partnerships!